Additionally, designing dual-target PROTACs—such as molecules that degrade both FAT10 and NOX4 simultaneously—may enable synergistic inhibition of AKI-related fibrosis and oxidative stress [21,55,58]. The gene discussed is NOX4; the disease is acute kidney injury.